Enhertu 100mg

Enhertu 100mg is a prescription anticancer medicine containing trastuzumab deruxtecan, an antibody-drug conjugate (ADC) used to treat certain types of cancer. It combines a monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2) with a cytotoxic substance that damages cancer cells. Its use depends on the cancer type, HER2 expression, previous treatments, and the patient’s clinical condition.

HER2 is a protein involved in cell growth and division. Some cancer cells produce excessive amounts of this protein, which can contribute to uncontrolled tumor growth. Enhertu binds to HER2 on cancer cells and delivers its attached chemotherapy agent into them. The released drug damages DNA, helping kill susceptible cancer cells and limit their multiplication.

Enhertu is used for specific cases of HER2-positive breast cancer, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, and certain other solid tumors, depending on the approved indication and tumor characteristics. It may also be prescribed for eligible patients with HER2-low breast cancer. Treatment selection requires an appropriate medical assessment and, when indicated, biomarker testing.

How Does Enhertu 100mg Work?

Enhertu 100mg is an intravenous targeted anticancer treatment containing trastuzumab deruxtecan. It belongs to a class of medicines called antibody-drug conjugates, which combine a cancer-targeting antibody with a potent chemotherapy agent.

The trastuzumab component attaches to HER2 proteins on susceptible cancer cells. After binding, the medicine is taken into the cells, where enzymes release deruxtecan, its cytotoxic component. Deruxtecan inhibits topoisomerase I, an enzyme involved in DNA replication, causing DNA damage that can lead to cancer cell death.

The released drug may also affect nearby cancer cells, including some that express lower levels of HER2. This activity can help the medicine work against certain tumors with different levels of HER2 expression, depending on the cancer type and treatment indication.

Enhertu is classified as a HER2-directed antibody-drug conjugate. Its effectiveness and suitability depend on the diagnosis, biomarker results, previous therapies, and the patient’s overall health. Because it can cause serious adverse reactions, including interstitial lung disease or pneumonitis, treatment requires specialist supervision and regular monitoring.

Dosage of Enhertu 100mg :

Enhertu 100mg is a powder for concentrate for solution for infusion. It is administered intravenously by qualified healthcare professionals in a medical facility. It must not be swallowed, injected at home, or used without an oncologist’s prescription.

The recommended dose for adults is generally based on body weight and the specific cancer being treated. For many approved indications, the usual dose is 5.4 mg/kg every three weeks. For HER2-positive gastric or gastroesophageal junction adenocarcinoma, the usual recommended dose is 6.4 mg/kg every three weeks. The applicable dose depends on the current prescribing information and treatment indication.

The 100mg vial strength does not mean that every patient receives a single 100mg dose. The healthcare team calculates the required amount according to body weight, diagnosis, and the prescribed regimen.

Treatment may continue until the cancer progresses or unacceptable side effects develop, depending on the indication. An oncologist may delay an infusion, reduce the dose, or discontinue treatment if serious adverse reactions occur. Patients should report new respiratory symptoms promptly and attend all recommended follow-up appointments.

Benefits of Using Enhertu 100mg :

Enhertu 100mg is a targeted anticancer medicine used for eligible patients with specific cancers involving HER2 expression or other qualifying tumor characteristics. Its potential benefits depend on the approved indication and individual treatment response.

Enhertu combines a HER2-directed antibody with a cytotoxic drug, allowing the treatment to deliver its active anticancer component to susceptible cells.

It may be prescribed for eligible patients with HER2-positive breast cancer, depending on previous treatments and the applicable indication.

For certain patients with HER2-low breast cancer, Enhertu provides a targeted treatment option when the required clinical criteria are met.

Enhertu is also used to treat eligible patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma after specified previous treatments.

For certain other advanced solid tumors with qualifying HER2 characteristics, it may be an option when the relevant regulatory criteria are satisfied and suitable alternatives are limited or unavailable.

By damaging the DNA of susceptible cancer cells, Enhertu may help control tumor growth and delay disease progression in appropriate patients. The extent and duration of benefit vary between individuals.

Treatment is administered through scheduled intravenous infusions, allowing healthcare professionals to monitor patients and manage adverse reactions during therapy.

Side Effects of Enhertu 100mg :

Enhertu may cause mild, moderate, or serious side effects. The likelihood and severity vary according to the patient, treatment regimen, and other medical factors. Commonly reported adverse reactions include:

• Nausea, vomiting, and reduced appetite
• Fatigue and weakness
• Diarrhea or constipation
• Hair loss
• Low blood cell counts, including anemia, neutropenia, and thrombocytopenia
• Increased liver enzyme levels
• Mouth sores and abdominal discomfort

A particularly serious risk is interstitial lung disease (ILD) or pneumonitis, which can cause inflammation in the lungs. Seek immediate medical assessment for a new or worsening cough, shortness of breath, fever, or other unexplained respiratory symptoms. Severe cases can be life-threatening.

Enhertu may also cause serious infections due to low blood cell counts, infusion-related reactions, and, in some patients, heart problems. The healthcare team may perform blood tests and assess cardiac function before and during treatment, as appropriate.

Tell your oncologist about all medicines you take and any new symptoms. Do not delay reporting possible serious adverse reactions. Treatment should be managed by qualified oncology professionals, who can determine whether an infusion should be delayed, the dose adjusted, or therapy discontinued.

Conclusion :

Enhertu 100mg (trastuzumab deruxtecan) is a prescription antibody-drug conjugate used to treat certain cancers based on tumor characteristics and approved indications. The dose and duration depend on the diagnosis and individual response. Specialist supervision and monitoring are essential because serious side effects, particularly lung inflammation, can occur.

Important Medical Warning :

Use Enhertu strictly under the direction of an oncologist. It is administered by qualified healthcare professionals through intravenous infusion. Do not attempt to prepare or administer this medicine yourself. Follow all instructions regarding treatment, laboratory tests, and follow-up appointments. Report new breathing problems immediately, and discuss pregnancy, breastfeeding, other medicines, and existing medical conditions with your healthcare team before treatment begins.